title: Reply to Passamonti et al: ruxolitinib and survival improvement in patients with myelofibrosis.
authors.affiliation: Center for the Study of Myelofibrosis, IRCCS Policlinico S. Matteo Foundation, Pavia, Italy.
authors.forename: G
authors.initials: G
authors.lastname: Barosi
authors.affiliation: Haematology Research Centre, Division of Experimental Medicine, Department of Medicine, Imperial College London, London, UK.
authors.forename: R P
authors.initials: RP
authors.lastname: Gale
mesh_terms: D006801:Humans; D053612:Janus Kinases / Q000037:antagonists & inhibitors*; D009196:Myeloproliferative Disorders / Q000188:drug therapy* / Q000401:mortality*; D011720:Pyrazoles / Q000008:administration & dosage* / Q000009:adverse effects*
chemical_list: D011720:Pyrazoles; D053612:Janus Kinases